Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$41.9K Sell
1,739
-34
-2% -$889 0.02% 216
2026
Q1
$49.8K Buy
1,773
+193
+12% +$5.14K 0.03% 205
2025
Q4
$39.3K Sell
1,580
-8,300
-84% -$209K 0.02% 219
2025
Q3
$252K Buy
9,880
+3,910
+65% +$96.5K 0.09% 132
2025
Q2
$145K Sell
5,970
-267
-4% -$6.23K 0.06% 166
2025
Q1
$158K Sell
6,237
-795
-11% -$20.8K 0.06% 163
2024
Q4
$187K Buy
7,032
+91
+1% +$2.47K 0.07% 150
2024
Q3
$201K Buy
6,941
+1,931
+39% +$56.3K 0.08% 150
2024
Q2
$157K Buy
5,010
+342
+7% +$9.42K 0.07% 158
2024
Q1
$134K Hold
4,668
0.06% 163
2023
Q4
$134K Buy
+4,668
New +$141K 0.06% 163

Other funds holding PFE

Sachetta's PFE Position: Q2 2026 in Review

Sachetta reduced its Pfizer (PFE) stake by 1.9% in Q2 2026, selling an estimated $889 and leaving 1,739 shares worth $41.9K. The position accounts for 0.02% of the portfolio, ranked #216.

Sachetta first reported a position in PFE in Q4 2023 and has held it in 11 quarters since. The position peaked at $252K in Q3 2025. 594 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Sachetta held 1,739 shares of Pfizer worth $41.9K as of Q2 2026.
  • Sachetta sold 34 Pfizer shares in Q2 2026, an estimated $889.
  • Pfizer made up 0.02% of Sachetta's portfolio in Q2 2026, its #216 holding.
  • Sachetta first reported a position in Pfizer in Q4 2023 and has held it in 11 quarters since.
  • Sachetta's Pfizer position peaked at $252K in Q3 2025.
  • 594 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Sachetta's 13F filing for Q2 2026, filed 15 Jul 2026.